| ¡ Regístrese ahora en R3i! TM Davis, R Ting, JD Best, MW Donoghoe, PL Drury, DR Sullivan, ... | | |
| # 66 Survival of PARP inhibitor (PARPi) naïve ovarian cancer patients with a BRCA-mutation receiving maintenance olaparib after chemotherapy for first recurrence. An … JA Ledermann, I Ray-Coquard, R Penson, C Lee, A Oza, J Korach, ... International Journal of Gynecologic Cancer 33 (Suppl 3), 2023 | | 2023 |
| 0284: Presenting Symptoms of Epithelial Ovarian Cancer IM Lataifeh, DE Marsden, G Roberston, V Gebski, N Hacker International Journal of Gynecologic Cancer 16 (Suppl 3), 2006 | | 2006 |
| 10-Year axillary recurrence in the RACS SNAC1 randomised trial of sentinel lymph node-based management versus routine axillary lymph node dissection I Campbell, N Wetzig, O Ung, D Espinoza, G Farshid, J Collins, J Kollias, ... The Breast 70, 70-75, 2023 | 3 | 2023 |
| 1350-P: Risk Models for the Development of Cardiovascular and Microvascular Events in Adults with Type 2 Diabetes in the FIELD Study K LEUNG ONG, RL O'CONNELL, AS JANUSZEWSKI, MW DONOGHOE, ... Diabetes 72 (Supplement_1), 2023 | | 2023 |
| 18LBA A GCIG randomized phase III study of carboplatin (C) & pegylated liposomal doxorubicin (PLD)(CD) vs carboplatin (C) & paclitaxel (P)(CP): CALYPSO results in partially … P Vasey, R Largillier, M Gropp, V Gebski, R Sandvei, L Elit, ... EJC Supplements 3 (7), 11, 2009 | 6 | 2009 |
| 2. Statistics in Clinical Oncology. John Crowley (ed.), Marcel Dekker, New York, 2001. Price: $175.00. ISBN: 0‐8247‐9025‐1 V Gebski Statistics in Medicine 23 (13), 2151-2153, 2004 | | 2004 |
| 204. THE TUMOUR IMMUNE MICROENVIRONMENT IN OESOPHAGEAL ADENOCARCINOMA HAS PROGNOSTIC SIGNIFICANCE J Lonie, S Brosda, L Aoude, V Bonazzi, K Patel, G Lampe, L Koufariotis, ... Diseases of the Esophagus 35 (Supplement_2), doac051. 204, 2022 | | 2022 |
| 2044 Feasibility of trials to assess safety and toxicity of peri-operative and post-operative adjuvant therapy for hepatic metastases from colorectal cancer D Goldstein, J Fawcett, J Bridgewater, M Choti, K Wilson, V Gebski, ... European Journal of Cancer 3 (51), S343, 2015 | 2 | 2015 |
| 2200 TOPGEAR: A randomized phase M/MI trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric … T Leong, BM Smithers, M Michael, V Gebski, J Simes, A Boussioutas, ... European Journal of Cancer 3 (51), S399-S400, 2015 | | 2015 |
| 2703 Computed tomography is more sensitive than CA 125 in detecting disease progression in patients with platinum-resistant ovarian cancer: Analysis of the AURELIA trial K Lindeman, G Kristensen, MR Mirza, L Davies, F Hilpert, I Romero, ... European Journal of Cancer 3 (51), S532-S533, 2015 | 2 | 2015 |
| 273 Efficacy of Sacral Nerve Stimulation for Treating Slow Transit Constipation: A Randomised, Double-Blind, Placebo-Controlled, 2 Phase Crossover Study PG Dinning, LM Hunt, VE Patton, V Gebski, MP Jones, P Stewart, ... Gastroenterology 5 (144), S-61, 2013 | 3 | 2013 |
| 280. MULTI-OMIC FEATURES OF OESOPHAGEAL ADENOCARCINOMA PATIENTS PRE-TREATED WITH PREOPERATIVE NEOADJUVANT THERAPY M Naeini, F Newell, LG Aoude, VF Bonazzi, K Patel, G Lampe, ... Diseases of the Esophagus 35 (Supplement_2), doac051. 280, 2022 | | 2022 |
| 57 Weight perception and sociodemographic characteristics following endometrial cancer treatment M Janda, V Gebski, P Forder, A Obermair International Journal of Gynecological Cancer 29 (Suppl 3), A32-A32, 2019 | | 2019 |
| 586P Minimal residual disease (MRD) detection using a tumour naïve circulating tumour DNA (ctDNA) assay in patients (pts) with resected colorectal cancer (CRC) in the phase III … D Day, A Starus, V Gebski, J Simes, T Hayes, S Padinharakam, ... Annals of Oncology 34, S426-S427, 2023 | 2 | 2023 |
| 6001 International randomised phase III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) in first line treatment of metastatic colorectal cancer (mCRC … N Tebbutt, V Gebski, K Wilson, M Cummins, B Robinson, A Broad, ... EJC Supplements 2 (7), 321, 2009 | 15 | 2009 |
| 6539 The difference in standardized uptake value on 18F-FDG-PET before and after pre-operative chemotherapy is a prognostic factor for recurrence and survival in patients with … F Chionh, D Handolias, A Poon, V Gebski, S Dayan, A Aly, N Tebbutt EJC Supplements 2 (7), 373, 2009 | | 2009 |
| 6559 POSTER A prognostic index (PI) for predicting lung cancer patients with multiple brain metastases who may not benefit from whole brain radiotherapy (WBRT) due to early death P Sundaresan, R Yeghiaian-Alvandi, V Gebski EJC Supplements 4 (5), 375, 2007 | | 2007 |
| 753P Adverse events experienced by patients in the placebo arm of maintenance therapy trials in advanced ovarian cancer S Simon, K Francis, J Dalrymple, V Gebski, S Lord, M Friedlander, CK Lee Annals of Oncology 32, S745, 2021 | | 2021 |
| 915 Long-term quality of life (QoL) following prostate irradiation: relationship to anorectal symptoms employing a proctitis-specific QoL instrument S Turner, A Kneebone, T Bolin, N Spry, V Gebski EJC Supplements 5 (1), S275, 2003 | | 2003 |
